Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: October 2, 2023 (Event Date); October 4, 2023 (Closing Date)
Reporting Period: Specific event reporting regarding a public offering.
The Company entered into an underwriting agreement with Ladenburg Thalmann & Co. Inc. to conduct a registered public offering of Class A Units (Common Stock and Warrants) and Class B Units (Series E Convertible Preferred Stock and Warrants). The offering closed on October 4, 2023.
Key Financial Metrics and Capital Structure
Offering Proceeds: Net proceeds to the Company were approximately $3.35 million after deducting underwriting discounts, commissions, and estimated offering expenses.
Securities Issued:
- Common Stock: 2,232,221 shares issued (including 688,217 from partial overallotment).
- Series E Convertible Preferred Stock: 5,728,723 shares issued.
- Series E Warrants: Warrants to purchase 7,960,944 shares of Common Stock at an exercise price of $0.55 per share (5.5-year term).
- Series F Warrants: Warrants to purchase 7,960,944 shares of Common Stock at an exercise price of $0.55 per share (1.5-year term).
Outstanding Shares: Immediately following the offering, 4,562,620 shares of Common Stock were outstanding (excluding conversions and warrant exercises).
Offering Costs: Underwriting discount of 8.0%, management fee of 1.0% of gross proceeds, and reimbursement of expenses up to $145,000. Representative Warrants issued for 5.0% of the offering (398,047 shares) at an exercise price of $0.6875.
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational financial metrics. This report focuses solely on the capital raise transaction.
Material Changes Versus Prior Period
This filing reports a discrete capital event rather than a comparative period financial performance. The primary material change is the significant increase in authorized and outstanding equity securities and the receipt of $3.35 million in net cash proceeds. The Company also filed a Certificate of Designation for the Series E Convertible Preferred Stock.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary: The Company utilized the proceeds to fund operations. Insider participation included purchases by the CFO (112,727 Class A Units) and a Board Member (9,090 Class A Units).
Lock-Up Agreements: The Company, executive officers, directors, and certain stockholders are subject to a lock-up period preventing the sale of securities for 90 days from the Underwriting Agreement date or 15 days following Warrant Stockholder Approval, whichever is later.
Warrant Terms and Risks:
- Reset Provision: Series E Warrant exercise price may reset to 90% of the 5-day VWAP following a reverse stock split.
- Cashless Exercise: Series F Warrants include an alternate cashless exercise option.
- Conversion Limitations: Series E Preferred Stock conversion is subject to beneficial ownership limitations (4.99% or 9.99% caps).
Contingencies: Warrants are exercisable only after obtaining necessary stockholder approvals from Nasdaq Capital Market rules.
Important Facts for Investor Verification
- Net Proceeds: Verify the actual cash received ($3.35 million) against the Company's cash balance in subsequent filings.
- Dilution Impact: Assess the potential dilution from 7,960,944 Series E Warrants, 7,960,944 Series F Warrants, and 5,728,723 convertible Preferred Shares.
- Warrant Exercise Price: Confirm the $0.55 exercise price relative to the current trading price of INBS common stock.
- Lock-Up Expiration: Monitor the expiration of the 90-day lock-up period for insiders and major shareholders.
- Stockholder Approval: Verify the status of the required Nasdaq stockholder approval for warrant exercise.